DE69824421T2 - Verfahren zur Behandlung von lysosomalen Speicherkrankheiten mit ZNS-Beteiligung - Google Patents

Verfahren zur Behandlung von lysosomalen Speicherkrankheiten mit ZNS-Beteiligung Download PDF

Info

Publication number
DE69824421T2
DE69824421T2 DE69824421T DE69824421T DE69824421T2 DE 69824421 T2 DE69824421 T2 DE 69824421T2 DE 69824421 T DE69824421 T DE 69824421T DE 69824421 T DE69824421 T DE 69824421T DE 69824421 T2 DE69824421 T2 DE 69824421T2
Authority
DE
Germany
Prior art keywords
disease
storage
mice
dnj
lysosomal storage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69824421T
Other languages
German (de)
English (en)
Other versions
DE69824421D1 (de
Inventor
M. Frances PLATT
R. Gabrielle NEISES
A. Raymond DWEK
Terry D. Butters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of DE69824421D1 publication Critical patent/DE69824421D1/de
Application granted granted Critical
Publication of DE69824421T2 publication Critical patent/DE69824421T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69824421T 1997-01-13 1998-01-13 Verfahren zur Behandlung von lysosomalen Speicherkrankheiten mit ZNS-Beteiligung Expired - Lifetime DE69824421T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US782321 1997-01-13
US08/782,321 US5798366A (en) 1993-05-13 1997-01-13 Method for treatment of CNS-involved lysosomal storage diseases
PCT/US1998/000031 WO1998030219A1 (en) 1997-01-13 1998-01-13 Method for treatment of cns-involved lysosomal storage diseases

Publications (2)

Publication Number Publication Date
DE69824421D1 DE69824421D1 (de) 2004-07-15
DE69824421T2 true DE69824421T2 (de) 2005-03-03

Family

ID=25125672

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824421T Expired - Lifetime DE69824421T2 (de) 1997-01-13 1998-01-13 Verfahren zur Behandlung von lysosomalen Speicherkrankheiten mit ZNS-Beteiligung

Country Status (11)

Country Link
US (1) US5798366A (https=)
EP (2) EP1491196A3 (https=)
JP (1) JP2001508064A (https=)
AT (1) ATE268598T1 (https=)
AU (1) AU5813898A (https=)
CA (1) CA2278507C (https=)
DE (1) DE69824421T2 (https=)
DK (1) DK1007043T3 (https=)
ES (1) ES2223118T3 (https=)
PT (1) PT1007043E (https=)
WO (1) WO1998030219A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
WO2000066105A2 (en) * 1999-04-30 2000-11-09 The Trustees Of Boston College Treatment of epilepsy with imino sugars
EP1196190B1 (en) 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
AU2003246942B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
US7994198B2 (en) * 2002-07-17 2011-08-09 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
AU2003302724A1 (en) * 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
EP2857036B1 (en) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
GB0313677D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
DE102004029310A1 (de) * 2004-06-17 2005-12-29 Clariant Gmbh Hochkonzentrierte, wässrige Formulierungen von Oligo-und Polyestern
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
US7884115B2 (en) * 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
CA2731346A1 (en) * 2010-02-09 2011-08-09 The Hospital For Sick Children Compounds for the treatment of lysosomal storage diseases
EP3318277A1 (en) * 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) * 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) * 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives

Also Published As

Publication number Publication date
EP1007043B9 (en) 2004-12-22
ATE268598T1 (de) 2004-06-15
DE69824421D1 (de) 2004-07-15
WO1998030219A1 (en) 1998-07-16
EP1491196A3 (en) 2005-03-16
DK1007043T3 (da) 2004-10-11
JP2001508064A (ja) 2001-06-19
CA2278507A1 (en) 1998-07-16
EP1007043A1 (en) 2000-06-14
AU5813898A (en) 1998-08-03
EP1007043B1 (en) 2004-06-09
PT1007043E (pt) 2004-10-29
EP1491196A2 (en) 2004-12-29
US5798366A (en) 1998-08-25
CA2278507C (en) 2007-08-28
ES2223118T3 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
DE69824421T2 (de) Verfahren zur Behandlung von lysosomalen Speicherkrankheiten mit ZNS-Beteiligung
DE69401658T2 (de) Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese
DE69625518T2 (de) Wirkstoff zur behandlung neurodegenerativer störungen
DE69735669T2 (de) Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
DE69233195T2 (de) Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose
DE69125523T2 (de) Verwendung eines Modulators der Proteinphosphorylierung zur Behandlung der Amyloidosis in Zusammenhang mit der Alzheimerschen Krankheit
DE69224080T2 (de) Verwendung von nsaid zur behandlung von demenz
DE3417857A1 (de) Arzneimittel mit antianoxischer und zerebral-metabolischer wirkung
DE69328618T2 (de) Medikamente auf der Basis von Docosahexaensäure, als Plättchenaggregationshemmer und gegen cerebralen Mangel an Fettsäuren, und Verfahren zur Herstellung.
DE68913756T2 (de) In vivo cytoprotektiv wirkende neurotrope alkohole.
DE3438821C2 (https=)
JP2002542195A (ja) グルコシルセラミド合成阻害剤の治療への使用
DE69323759T2 (de) Verwendung von toremifene für die behandlung von sle
Nandy Centrophenoxine: effects on aging mammalian brain
DE3805744C2 (de) Phenylcarbamate zur Hemmung der Acetylcholinesterase
Kanerva et al. Ichthyosis hystrix (Curth-Macklin): light and electron microscopic studies performed before and after etretinate treatment
DE4232899C2 (de) Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer
Suzuki et al. Studies on the pathogenesis of Krabbe’s leukodystrophy: cellular reaction of the brain to exogenous galactosylsphingosine, monogalactosyl diglyceride, and lactosylceramide
DE102007063535A1 (de) Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
EP1056467B1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
WO1998008511A1 (de) Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-one zur herstellung einer pharmazeutischen zubereitung für die behandlung der alzheimer-krankheit
Drenckhahn et al. Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs
EP1064002B1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
Oldfors et al. Storage of lipofuscin in neurons in mucopolysaccharidosis: Report on a case of Sanfilippo's syndrome with histochemical and electron-microscopic findings
Walkley et al. Lysosomal diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ACTELION PHARMACEUTICALS LTD., ALLSCHWIL, CH